Armata Pharmaceuticals (ARMP) Liabilities and Shareholders Equity (2016 - 2026)
Quarterly results put Liabilities and Shareholders Equity at $69.8 million for Q1 2026, down 20.0% from a year ago — trailing twelve months through Mar 2026 was $317.0 million (down 16.63% YoY), and the annual figure for FY2025 was $76.9 million, down 11.05%.
Armata Pharmaceuticals has reported Liabilities and Shareholders Equity over the past 14 years, most recently at $69.8 million for Q1 2026.
- Liabilities and Shareholders Equity reached $69.8 million in Q1 2026 per ARMP's latest filing, down from $76.9 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $120.4 million in Q1 2024 and bottomed at $69.8 million in Q1 2026.
- Median Liabilities and Shareholders Equity over the past 5 years was $98.2 million (2024), compared with a mean of $96.2 million.
- The largest annual shift saw Liabilities and Shareholders Equity skyrocketed 117.67% in 2022 before it decreased 27.51% in 2025.
- Over 5 years, Liabilities and Shareholders Equity stood at $95.8 million in 2022, then grew by 2.64% to $98.4 million in 2023, then dropped by 12.12% to $86.4 million in 2024, then dropped by 11.05% to $76.9 million in 2025, then dropped by 9.21% to $69.8 million in 2026.
- Business Quant data shows Liabilities and Shareholders Equity for ARMP at $69.8 million in Q1 2026, $76.9 million in Q4 2025, and $89.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 14.93 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | 37.37 Mn |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 1.73 Bn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | 78.88 Mn |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 33.89 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 26.48 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 40.87 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | 23.64 Mn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 5.13 Bn |
| 10 | Armata Pharmaceuticals | 301.92 Mn | 297.17 Mn | - | 69.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 69.80 Mn |
| Dec 31, 2025 | 76.88 Mn |
| Sep 30, 2025 | 89.52 Mn |
| Jun 30, 2025 | 80.79 Mn |
| Mar 31, 2025 | 87.25 Mn |
| Dec 31, 2024 | 86.44 Mn |
| Sep 30, 2024 | 98.24 Mn |
| Jun 30, 2024 | 108.31 Mn |
| Mar 31, 2024 | 120.36 Mn |
| Dec 31, 2023 | 98.36 Mn |
| Sep 30, 2023 | 112.76 Mn |
| Jun 30, 2023 | 101.21 Mn |
| Mar 31, 2023 | 108.78 Mn |
| Dec 31, 2022 | 95.83 Mn |
| Sep 30, 2022 | 92.88 Mn |
| Jun 30, 2022 | 100.98 Mn |
| Mar 31, 2022 | 107.77 Mn |
| Dec 31, 2021 | 69.77 Mn |
| Sep 30, 2021 | 42.67 Mn |
| Jun 30, 2021 | 48.28 Mn |
| Mar 31, 2021 | 52.85 Mn |
| Dec 31, 2020 | 39.52 Mn |
| Sep 30, 2020 | 45.68 Mn |
| Jun 30, 2020 | 49.46 Mn |
| Mar 31, 2020 | 44.10 Mn |
| Dec 31, 2019 | 25.45 Mn |
| Sep 30, 2019 | 29.30 Mn |
| Jun 30, 2019 | 34.92 Mn |
| Mar 31, 2019 | 9.62 Mn |
| Dec 31, 2018 | 14.55 Mn |
| Sep 30, 2018 | 10.62 Mn |
| Jun 30, 2018 | 11.72 Mn |
| Mar 31, 2018 | 14.40 Mn |
| Dec 31, 2017 | 11.14 Mn |
| Sep 30, 2017 | 13.78 Mn |
| Jun 30, 2017 | 15.11 Mn |
| Mar 31, 2017 | 14.30 Mn |
| Dec 31, 2016 | 18.15 Mn |
| Sep 30, 2016 | 26.04 Mn |
| Jun 30, 2016 | 29.28 Mn |